Jacqueline L. Yee

Jacqueline L. Yee

Auto-generated profile, based on publicly available information

Jacqueline L. Yee

University of California San Francisco 2 Biomedical Sciences Graduate Program San Francisco, California

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Science
Verified
Journal Article
Open access
GAGreg M. Allen
Greg M. Allen
NFNicholas W. Frankel
Nicholas W. Frankel
NRNishith R. Reddy
Nishith R. Reddy
HBHersh K. Bhargava
Hersh K. Bhargava
MYMaia A. Yoshida
Maia A. Yoshida
WLWendell A. Lim
Wendell A. Lim
Chimeric antigen receptor (CAR) T cells are ineffective against solid tumors with immunosuppressive microenvironments. To overcome suppression, we engineered circuits in which tumor-specific synNotch receptors locally induce production of the cytokine IL-2. These circuits potently enhance CAR T cell infiltration and clearance of immune-excluded tumors, without systemic toxicity. The most effective IL-2 induction circuit acts in an autocrine and T cell receptor (TCR)- or CAR-independent manner, bypassing suppression mechanisms including consumption of IL-2 or inhibition of TCR signaling. These engineered cells establish a foothold in the target tumors, with synthetic Notch–induced IL-2 production enabling initiation of CAR-mediated T cell expansion and cell killing. Thus, it is possible to reconstitute synthetic T cell circuits that activate the outputs ultimately required for an antitumor response, but in a manner that evades key points of tumor suppression.

15 October 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
NCNam Woo Cho
Nam Woo Cho
SGSophia M. Guldberg
Sophia M. Guldberg
BNBarzin Y. Nabet
Barzin Y. Nabet
JYJie Zeng Yu
Jie Zeng Yu
EKEun Ji Kim
Eun Ji Kim
MSMatthew H. Spitzer
Matthew H. Spitzer
Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in contrast to ICI-responsive tumors. Resistant tumors were distinguished by high expression of IL1 receptor 1, enabling a synergistic response to IL1 and TNFα to induce G-CSF, CXCL1, and CXCL2 via NF-κB signaling, supporting immunosuppressive neutrophil accumulation in tumor. Perturbation of this inflammatory resistance circuit sensitized tumors to ICIs. Paradoxically, T cells drove this resistance circuit via TNFα both in vitro and in vivo. Evidence of this inflammatory resistance circuit and its impact also translated to human cancers. These data support a mechanism of ICI resistance, wherein treatment-induced T-cell activity can drive resistance in tumors responsive to IL1 and TNFα, with important therapeutic implications.

13 April 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
SKSujit Kashyap
Sujit Kashyap
JSJun Hyung Sin
Jun Hyung Sin
SGSophia M. Guldberg
Sophia M. Guldberg
JYJacqueline L. Yee
Jacqueline L. Yee
MLMaya Lopez-Ichikawa
Maya Lopez-Ichikawa
MWMichael Waterfield
Michael Waterfield
CD8+ T-cell exhaustion limits the immune response to tumors because of ineffective T-cell effector functions. Thus, therapies that inhibit T-cell exhaustion are critical for optimizing cancer treatment. Recent studies have implicated epigenetic proteins in T-cell exhaustion. In this study, we identified activating transcription factor 7–interacting protein (ATF7ip) as an epigenetic protein critical for inducing T-cell exhaustion. Loss of Atf7ip in CD8+ T cells resulted in decreased terminal exhaustion and increased numbers of progenitor-exhausted cells in both chronic viral infections and cancer. Given the decreased T-cell terminal exhaustion observed with Atf7ip deficiency in CD8+ T cells, this may be one mechanism that leads to decreased tumor burden. Mechanistically, ATF7ip functions to stimulate the deposition of repressive H3K9me3 at critical immune-effector gene loci, such as Il7r and Il2, leading to enhanced exhaustion. Our data suggest that ATF7ip may be a rational target for deletion in adoptive T-cell therapies to reduce CD8+ T-cell exhaustion.


3 February 2025
Verified
Other
Open access
NCNam Woo Cho
Nam Woo Cho
SGSophia M. Guldberg
Sophia M. Guldberg
BNBarzin Y. Nabet
Barzin Y. Nabet
JYJie Zeng Yu
Jie Zeng Yu
EKEun Ji Kim
Eun Ji Kim
MSMatthew H. Spitzer
Matthew H. Spitzer
Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in contrast to ICI-responsive tumors. Resistant tumors were distinguished by high expression of IL1 receptor 1, enabling a synergistic response to IL1 and TNFα to induce G-CSF, CXCL1, and CXCL2 via NF-κB signaling, supporting immunosuppressive neutrophil accumulation in tumor. Perturbation of this inflammatory resistance circuit sensitized tumors to ICIs. Paradoxically, T cells drove this resistance circuit via TNFα both in vitro and in vivo. Evidence of this inflammatory resistance circuit and its impact also translated to human cancers. These data support a mechanism of ICI resistance, wherein treatment-induced T-cell activity can drive resistance in tumors responsive to IL1 and TNFα, with important therapeutic implications.